Source link : https://www.newshealth.biz/health-news/chemoradiation-plus-immunotherapy-fails-to-improve-survival-in-limited-stage-sclc/
Adding immunotherapy to chemoradiation therapy (CRT) for limited-stage small cell lung cancer (SCLC) failed to improve survival in a randomized trial. As compared with CRT alone, concurrent atezolizumab (Tecentriq) did not improve overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), or time to local failure (TTLF). Interestingly, patients who received radiation therapy on […]
Author : News Health
Publish date : 2024-10-02 20:20:11
Copyright for syndicated content belongs to the linked Source.